英夫利西单抗治疗强直性脊柱炎的疗效和安全性评价

To Evaluate the Efficacy and Safety of Infliximab in the Treatment of Ankylosing Spondylitis

目的探讨英夫利西单抗治疗强直性脊柱炎的疗效和安全性。方法于2015年1—12月,整群选取福州市第二医院风湿科收治的84例强直性脊柱炎患者,按照数字表法随机分为研究组和对照组,其中对照组采用甲氨蝶呤、柳氮磺胺吡啶、来氟米特等传统药物治疗,而研究组在甲氨蝶呤、柳氮磺胺吡啶、来氟米特等传统药物治疗的基础上采用英夫利西单抗治疗,比较对照组和研究组患者的临床疗效及不良反应发生情况。结果研究组患者的临床治疗总有效率(95.24%)明显高于对照组(64.29%)(χ2=7.92,P<0.05)。研究组和对照组患者在治疗后,脊柱晨僵持续时间[(20.17±4.67)min]、ESR[(16.34±4.19)mm/h]、CRP[(10.23±2.34)mg/L]及疼痛程度[(1.22±0.54)分]等指标均较本组治疗前明显改善;但是,研究组的改善程度则明显优于对照组(t=4.67、8.76、4.32、6.53,P<0.05),差异有统计学意义。结论英夫利西单抗治疗强直性脊柱炎的疗效显著,不良反应发生率低,值得临床推广使用。

Objective To investigate the efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Methods Group selection from January 2015 to December 2015, 84 cases of ankylosing spondylitis patients in department of rheumatology Second hospital of Fuzhou City were randomly divided into study group and control group according to the digital table method, the control group was treated with conventional drug therapy. On the basis of the traditional drug, patients in the study group were treated with infliximab. Clinical therapeutic effect and adverse reaction were compared between the two groups. Results The total effective rate of the study group（95.24%） was significantly higher than that of the control group（64.29%）（χ^2=7.92, P〈0.05）. Two groups of patients after spinal stiffness continuous time [（20.17±4.67）min],ESR[（16.34±4.19）mm/h], CRP[（10.23±2.34）mg/L] and the extent of pain index[（1.22±0.54）score] were compared with those before the treatment group improved significantly, and degree of improvement in the study group was obviously better than that of the control group（t=4.67, 876, 4.32, 6.53, P〈0.05）,the difference was statisti cally significant. Conclusion The efficacy of infliximab in the treatment of ankylosing spondylitis was significant, and had low incidence of adverse reactions. It was worth for clinical use.